Af­ter Bio­gen ex­it, Mit­subishi Tan­abe Phar­ma links up with Sal­ix to de­vel­op amise­limod; Two drug de­vel­op­ers set up an­tibi­ot­ic col­lab­o­ra­tion

→ About two years af­ter Bio­gen $BI­IB walked away from Mit­subishi Tan­abe Phar­ma‘s MT-1303 (amise­limod), the Japan­ese drug­mak­er has joined forces with Bausch Health’s Sal­ix Phar­ma­ceu­ti­cals to de­vel­op the late-stage oral com­pound, which tar­gets the sphin­go­sine 1-phos­phate (S1P) re­cep­tor that is un­der­stood to play a role in au­toim­mune dis­eases, such as IBD and ul­cer­a­tive col­i­tis. Fi­nan­cial de­tails of the deal were not dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.